AUTHORS
Nicholas Short, MD, Eunice Sue Wang, MD2, Talha Badar, MD3, Omer Jamy, MD4, Caitlin Cohen, ANP5, Rebecca Burne6, Nathan Gobeil7, Mattéo Guillemard8, Dominick Latremouille-Viau, MSc9, Gabriel Marquez10, Annie Guerin, MSc11, David Wei, PhD12, Andrea Damon, PhD13, Elias Jabbour, MD14
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, TX, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Mayo Clinic Comprehensive Cancer Centre, Jacksonville, Florida, United States
4 UAB Medicine, Birmingham, Alabama, United States
5 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
6 Analysis Group Inc, Montreal, Canada
7 Analysis Group Inc, Montreal, Canada
8 Analysis Group Inc, Montreal, Canada
9 Analysis Group Inc, Montreal, Canada
10 Novartis Ireland Ltd., Dublin, Ireland
11 Analysis Group Inc, Montreal, Canada
12 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
13 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction: Asciminib, a tyrosine kinase inhibitor (TKI) and the first BCR::ABL1 inhibitor to specifically target the ABL myristoyl pocket, was initially FDA-approved in 2021 for chronic myeloid leukemia in chronic phase. Based on findings from early-phase trials, practice guidelines now recommend asciminib-based regimens as a treatment option for patients with newly diagnosed and relapsed/refractory Ph+ ALL. This study characterized US patients with Ph+ ALL treated with asciminib-based regimens and their real-world clinical outcomes.
Methods: This retrospective physician panel-based chart review collected de-identified data on adults who initiated asciminib for Ph+ ALL between October 2021 and June 2025. Eligible US-based oncologists/hematologists abstracted medical chart data using an online case report form. Real-world clinical outcomes included complete remission (CR)/CR with incomplete count recovery (CRi), measurable residual disease negativity (MRD-: MR4 or better/BCR::ABL1 ≤0.01%), and TKI-related events. Cumulative probability of initiating a subsequent TKI was estimated using Kaplan–Meier methods, including 95% confidence interval (CI).
Results: Fifty eligible patient charts (median age: 58 years [range: 18–85]; female: 48%; White: 68%, Black/African American: 20%, Hispanic/Latino: 10%; ECOG performance status 0: 10%, 1: 64%, ≥2: 26%; p190 transcript: 70%) were provided by 23 physicians (65% academic; 78% with ≥10 years’ experience). Asciminib was received as the first TKI in 10% of patients; 48% had received 1 prior TKI, 36% had received 2, and 6% had ≥3; 40% had prior ponatinib exposure. Prior chimeric antigen receptor T-cell (CAR-T), hematopoietic cell transplantation (HCT), and blinatumomab exposure were reported in 3 (6%), 2 (4%), and 11 (22%) patients, respectively. At asciminib initiation, 26% had a known T315I/A mutation.
Among patients who initiated asciminib as second-line or later therapy (n=45), reasons for initiation included lack of efficacy of prior therapy (53%; persistent MRD [22%], refractory [16%], or relapse [16%]), intolerance of prior TKI (33%), and other reasons (13%; maintenance, consolidation, or other). Asciminib was administered as monotherapy in 23 (46%) patients and in combination in 27 (54%) patients, most commonly with immunotherapy (n=16; 13 with blinatumomab), corticosteroids (n=9), or cytotoxic chemotherapy (n=4). In patients initiating asciminib as the first-line TKI (n=5), the primary reasons for selection were efficacy (n=4) and tolerability (n=1); front-line asciminib was received in combination with corticosteroids (n=3), blinatumomab (n=1), and dasatinib (n=1).
Overall, the median duration of asciminib therapy was 15 months [range 0.5–41]. Most patients initiated asciminib at 80 mg/day (82%). The 12-month cumulative probability of initiating a subsequent TKI was 6.3% (95% CI: 2.1–18.3%). No emergent T315I/A mutations were observed. During asciminib treatment, 84% of patients had physician-reported CR/CRi (CR: 68%), among whom 71% were MRD-. In the first-line setting (n=5), the median duration of therapy was 16 months [range 12–41]. All had CR/CRi (CR: 3/5; CRi: 2/5), and 2/5 achieved MRD-.
Among patients initiating asciminib due to lack of efficacy of prior TKI (n=24), 79% had CR/CRi on asciminib, among whom 84% were MRD-. Among those initiating asciminib due to intolerance (n=15), 87% had CR/CRi on asciminib, among whom 85% were MRD-. Eight patients were bridged to HCT/CAR-T consolidation after asciminib initiation (HCT, n=4; CAR-T, n=4).
Among all asciminib-treated patients with Ph+ ALL, 44% had no reported TKI-related events. The most common TKI-related events were fatigue (26%), nausea (24%), and hypertension (20%; half had baseline hypertension). Eight patients (16%) discontinued asciminib for tolerability reasons.
Conclusion: In this physician-reported real-world cohort, asciminib was used across diverse clinical scenarios in patients with Ph+ ALL, including after prior TKI intolerance or inadequate efficacy, in combination regimens, and as a bridge to HCT or CAR-T. High rates of CR/CRi and MRD- were observed during asciminib treatment, with a low cumulative probability of initiating a subsequent TKI at 12 months. These findings provide insight into contemporary real-world treatment patterns and outcomes associated with asciminib use in Ph+ ALL.
DISCLOSURES
Nicholas Short, MD: Sanofi - Honoraria; Astellas Pharma Inc - Honoraria; Pfizer Inc - Honoraria; BeiGene - Honoraria; AstraZeneca - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Takeda - Honoraria; Merck - Honoraria; Adaptive Biotechnologies - Honoraria; Xencor - Research Funding; Hemogenyx - Research Funding; Astellas Pharma Inc - Research Funding; Takeda - Research Funding; Nexcure - Research Funding; Remedy Plan - Research Funding; NextCure - Research Funding; Vironexis - Research Funding; Takeda Oncology - Research Funding; GSK - Research Funding; Stemline Therapeutics - Research Funding; Novartis - Research Funding; Ascentage - Research Funding; Honoraria - Research Funding; Pfizer Inc - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); AB Science - Consultancy (Includes expert testimony); NKARTA - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)